Recent Analyst Stock Rating News
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Get Started for Free
Evan Seigerman is an analyst at BMO Capital. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 07/02/2024
| Buy Now | Get Alert | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 07/02/2024 | INCY | Buy Now | Incyte | $58.86 | -18.45% | $52 → $48 | Downgrade | Market Perform → Underperform | Get Alert |
| 06/17/2024 | IRON | Buy Now | Disc Medicine | $46.47 | 50.63% | $50 → $70 | Reiterates | Outperform → Outperform | Get Alert |
| 05/31/2024 | VRTX | Buy Now | Vertex Pharmaceuticals | $471.25 | 6.1% | $480 → $500 | Maintains | Outperform | Get Alert |
| 05/02/2024 | NBIX | Buy Now | Neurocrine Biosciences | $140.11 | -1.51% | $129 → $138 | Maintains | Market Perform | Get Alert |
| 05/01/2024 | LLY | Buy Now | Eli Lilly and Co | $904.00 | 10.73% | $900 → $1001 | Maintains | Outperform | Get Alert |
| 05/01/2024 | INCY | Buy Now | Incyte | $58.86 | -11.65% | $56 → $52 | Maintains | Market Perform | Get Alert |
| 04/26/2024 | BMY | Buy Now | Bristol-Myers Squibb | $41.30 | 16.22% | $55 → $48 | Maintains | Market Perform | Get Alert |
| 04/02/2024 | IRON | Buy Now | Disc Medicine | $46.47 | 7.6% | — | Maintains | Outperform | Get Alert |
| 02/29/2024 | IRON | Buy Now | Disc Medicine | $46.47 | 72.15% | $70 → $80 | Maintains | Outperform | Get Alert |
| 02/14/2024 | BIIB | Buy Now | Biogen | $231.60 | 23.06% | $295 → $285 | Maintains | Outperform | Get Alert |
| 02/14/2024 | INCY | Buy Now | Incyte | $58.86 | 8.73% | $58 → $64 | Maintains | Market Perform | Get Alert |
| 02/07/2024 | LLY | Buy Now | Eli Lilly | $904.00 | -4.31% | $710 → $865 | Maintains | Outperform | Get Alert |
| 11/10/2023 | NBIX | Buy Now | Neurocrine Biosciences | $140.11 | -28.63% | $111 → $100 | Maintains | Market Perform | Get Alert |
| 11/09/2023 | BIIB | Buy Now | Biogen | $231.60 | 27.37% | $314 → $295 | Maintains | Outperform | Get Alert |
| 11/07/2023 | VRTX | Buy Now | Vertex Pharmaceuticals | $471.25 | -11.94% | $389 → $415 | Maintains | Outperform | Get Alert |
| 10/27/2023 | BMY | Buy Now | Bristol-Myers Squibb | $41.30 | 45.28% | → $60 | Downgrade | Outperform → Market Perform | Get Alert |
| 09/13/2023 | NBIX | Buy Now | Neurocrine Biosciences | $140.11 | -20.78% | $100 → $111 | Maintains | Market Perform | Get Alert |
| 08/09/2023 | LLY | Buy Now | Eli Lilly | $904.00 | -29.98% | $565 → $633 | Maintains | Outperform | Get Alert |
| 08/08/2023 | BIIB | Buy Now | Biogen | $231.60 | 45.08% | $347 → $336 | Maintains | Outperform | Get Alert |
| 08/02/2023 | INCY | Buy Now | Incyte | $58.86 | 15.53% | $70 → $68 | Maintains | Market Perform | Get Alert |
| 08/02/2023 | VRTX | Buy Now | Vertex Pharmaceuticals | $471.25 | -17.45% | $385 → $389 | Maintains | Outperform | Get Alert |
| 08/02/2023 | NBIX | Buy Now | Neurocrine Biosciences | $140.11 | -28.63% | $96 → $100 | Maintains | Market Perform | Get Alert |
| 07/28/2023 | BMY | Buy Now | Bristol-Myers Squibb | $41.30 | 91.28% | $87 → $79 | Maintains | Outperform | Get Alert |
| 07/26/2023 | BIIB | Buy Now | Biogen | $231.60 | 49.83% | $357 → $347 | Maintains | Outperform | Get Alert |
| 07/06/2023 | NBIX | Buy Now | Neurocrine Biosciences | $140.11 | -31.48% | $91 → $96 | Upgrade | Underperform → Market Perform | Get Alert |
| 06/12/2023 | IRON | Buy Now | Disc Medicine | $46.47 | 50.63% | $40 → $70 | Maintains | Outperform | Get Alert |
| 05/16/2023 | GILD | Buy Now | Gilead Sciences | $68.64 | 45.69% | $90 → $100 | Upgrade | Market Perform → Outperform | Get Alert |
| 05/04/2023 | LLY | Buy Now | Eli Lilly | $904.00 | -44.14% | $430 → $505 | Maintains | Outperform | Get Alert |
| 05/03/2023 | INCY | Buy Now | Incyte | $58.86 | 18.93% | $75 → $70 | Maintains | Market Perform | Get Alert |
| 05/02/2023 | VRTX | Buy Now | Vertex Pharmaceuticals | $471.25 | -18.3% | → $385 | Maintains | Outperform | Get Alert |
| 03/23/2023 | IRON | Buy Now | Disc Medicine | $46.47 | -13.92% | → $40 | Initiates | → Outperform | Get Alert |
| 02/28/2023 | GPCR | Buy Now | Structure Therapeutics | $40.81 | -1.99% | → $40 | Initiates | → Outperform | Get Alert |
| 02/08/2023 | VRTX | Buy Now | Vertex Pharmaceuticals | $471.25 | -24.67% | → $355 | Maintains | Outperform | Get Alert |
| 12/08/2022 | MRTX | Buy Now | Mirati Therapeutics | — | — | $110 → $59 | Downgrade | Outperform → Market Perform | Get Alert |
| 10/14/2022 | REPL | Buy Now | Replimune Group | $9.57 | 317.97% | $30 → $40 | Maintains | Outperform | Get Alert |
| 09/28/2022 | BIIB | Buy Now | Biogen | $231.60 | 55.44% | $217 → $360 | Upgrade | Market Perform → Outperform | Get Alert |
| 09/12/2022 | BMY | Buy Now | Bristol-Myers Squibb | $41.30 | 127.6% | $92 → $94 | Maintains | Outperform | Get Alert |
| 08/04/2022 | REGN | Buy Now | Regeneron Pharmaceuticals | $1.06K | -25.45% | $757 → $788 | Maintains | Outperform | Get Alert |
| 08/02/2022 | NUVB | Buy Now | Nuvation Bio | $3.15 | -20.63% | $8 → $2.5 | Downgrade | Outperform → Market Perform | Get Alert |
| 05/02/2022 | BMY | Buy Now | Bristol-Myers Squibb | $41.30 | 122.76% | $87 → $92 | Maintains | Outperform | Get Alert |
| 04/29/2022 | GILD | Buy Now | Gilead Sciences | $68.64 | -8.22% | $65 → $63 | Maintains | Market Perform | Get Alert |
| 04/29/2022 | LLY | Buy Now | Eli Lilly | $904.00 | -60.4% | $330 → $358 | Maintains | Outperform | Get Alert |
| 04/28/2022 | AMGN | Buy Now | Amgen | $310.46 | -21.73% | $263 → $243 | Maintains | Market Perform | Get Alert |
| 03/31/2022 | CADL | Buy Now | Candel Therapeutics | $6.49 | 84.9% | $18 → $12 | Maintains | Outperform | Get Alert |
| 03/30/2022 | BMY | Buy Now | Bristol-Myers Squibb | $41.30 | 96.13% | $74 → $81 | Maintains | Outperform | Get Alert |
| 03/22/2022 | NUVB | Buy Now | Nuvation Bio | $3.15 | 280.95% | $17 → $12 | Maintains | Outperform | Get Alert |
| 02/28/2022 | GILD | Buy Now | Gilead Sciences | $68.64 | -5.3% | $75 → $65 | Downgrade | Outperform → Market Perform | Get Alert |
| 02/04/2022 | BIIB | Buy Now | Biogen | $231.60 | 2.76% | $260 → $238 | Downgrade | Outperform → Market Perform | Get Alert |
| 01/20/2022 | VRTX | Buy Now | Vertex Pharmaceuticals | $471.25 | -41.86% | $202 → $274 | Upgrade | Market Perform → Outperform | Get Alert |
| 11/19/2021 | MRTX | Buy Now | Mirati Therapeutics | — | — | — | Initiates | → Outperform | Get Alert |
| 11/19/2021 | PFE | Buy Now | Pfizer | $28.21 | 112.69% | — | Initiates | → Outperform | Get Alert |
| 11/19/2021 | BMY | Buy Now | Bristol-Myers Squibb | $41.30 | 74.33% | — | Initiates | → Outperform | Get Alert |
| 11/19/2021 | LLY | Buy Now | Eli Lilly | $904.00 | -65.6% | — | Initiates | → Outperform | Get Alert |
| 11/19/2021 | INCY | Buy Now | Incyte | $58.86 | 27.42% | — | Initiates | → Market Perform | Get Alert |
| 11/19/2021 | BIIB | Buy Now | Biogen | $231.60 | 36.01% | — | Initiates | → Outperform | Get Alert |
| 11/19/2021 | AMGN | Buy Now | Amgen | $310.46 | -26.56% | — | Initiates | → Market Perform | Get Alert |
| 11/19/2021 | NBIX | Buy Now | Neurocrine Biosciences | $140.11 | -45.76% | — | Initiates | → Underperform | Get Alert |
| 11/19/2021 | VRTX | Buy Now | Vertex Pharmaceuticals | $471.25 | -57.14% | — | Initiates | → Market Perform | Get Alert |
| 04/21/2020 | VRTX | Buy Now | Vertex Pharmaceuticals | $471.25 | -36.76% | $258 → $298 | Maintains | Outperform | Get Alert |
